- HUTCHMED released its 2025 sustainability report, closing its 2020-2025 target cycle with all social and governance targets met, most environmental targets met.
- Carbon emissions intensity fell 48% versus 2020 baseline; energy intensity declined 38%.
- Company completed its first climate-related financial impact assessment, quantifying exposures from physical risks such as flooding, heat stress, plus transition risks under multiple scenarios.
- Workforce remained gender-balanced at 55% female; female representation on board reached 40%.
- Since 2018, more than 300,000 patients worldwide have received its oncology medicines commercially; FRUZAQLA secured national reimbursement in markets including Japan, Spain, England and Wales.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260409-12099398), on April 09, 2026, and is solely responsible for the information contained therein.
Comments